You are here

Subcutaneous Velcade Gains FDA Nod

The Takeda Oncology Company said Monday that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for its Velcade (bortezomib) drug to include subcutaneous administration.

The FDA nod is for all approved indications of Velcade — multiple myeloma and mantle cell lymphoma after at least one prior therapy, the company said.

The approval was based on results from a randomized Phase 3 trial in 222 patients with relapsed multiple myeloma who had not previously taken Velcade. The primary goal of the trial was to show that single-agent subcutaneous Velcade retained at least 60 percent of the overall response rate after four cycles compared to single-agent intravenous drug administration. The secondary endpoints of the study included safety and tolerability, time to progression, progression-free survival and one-year overall survival.

Read the full article here.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs